Research Analysts Set Expectations for BCRX FY2026 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for BioCryst Pharmaceuticals in a report issued on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse expects that the biotechnology company will earn $0.21 per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $20.00 price objective on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share.

A number of other equities analysts have also recently issued reports on BCRX. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 22nd. Barclays boosted their target price on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a research note on Wednesday, May 7th. Wedbush initiated coverage on BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price target for the company. Needham & Company LLC raised their price objective on BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the company a "buy" rating in a report on Tuesday, May 6th. Finally, HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $16.56.

BioCryst Pharmaceuticals Stock Performance

Shares of BioCryst Pharmaceuticals stock traded down $0.10 during trading on Tuesday, reaching $11.01. 2,164,422 shares of the company's stock were exchanged, compared to its average volume of 3,036,213. The firm's 50-day moving average price is $9.07 and its 200 day moving average price is $8.31. BioCryst Pharmaceuticals has a 1-year low of $5.92 and a 1-year high of $11.31. The company has a market cap of $2.30 billion, a P/E ratio of -18.05 and a beta of 1.11.

Institutional Trading of BioCryst Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in BioCryst Pharmaceuticals by 7.8% during the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock worth $164,616,000 after purchasing an additional 1,583,826 shares during the last quarter. Alkeon Capital Management LLC raised its stake in BioCryst Pharmaceuticals by 1.7% during the first quarter. Alkeon Capital Management LLC now owns 7,214,021 shares of the biotechnology company's stock worth $54,105,000 after buying an additional 120,199 shares during the last quarter. Millennium Management LLC raised its stake in BioCryst Pharmaceuticals by 382.6% during the first quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company's stock worth $28,597,000 after buying an additional 3,022,769 shares during the last quarter. Caligan Partners LP lifted its holdings in BioCryst Pharmaceuticals by 16.0% in the fourth quarter. Caligan Partners LP now owns 2,995,932 shares of the biotechnology company's stock valued at $22,529,000 after buying an additional 412,347 shares during the period. Finally, Two Sigma Advisers LP boosted its position in BioCryst Pharmaceuticals by 14.6% during the fourth quarter. Two Sigma Advisers LP now owns 2,499,812 shares of the biotechnology company's stock valued at $18,799,000 after acquiring an additional 318,800 shares during the last quarter. Institutional investors own 85.88% of the company's stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.